查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1698153

髓样甲状腺癌市场－全球产业规模、份额、趋势、机会和预测，按治疗、最终用户、地区和竞争细分，2020-2030 年预测

Medullary Thyroid Cancer Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment, By End-User, By Region, & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球髓样甲状腺癌市场价值为 14.5 亿美元，预计在预测期内将呈现令人印象深刻的成长，到 2030 年的复合年增长率为 8.45%。髓样甲状腺癌 (MTC) 是一种罕见但具有临床意义的甲状腺癌，起源于甲状腺的滤泡旁细胞 (C 细胞)。它约占所有甲状腺癌的1-2％。全球髓样甲状腺癌市场涵盖与这种复杂且具有挑战性的疾病的诊断、管理和研究相关的各种产品、服务和治疗。

市场概览
预测期 2026-2030
2024年市场规模 14.5亿美元
2030年市场规模 23.6亿美元
2025-2030 年复合年增长率 8.45%
成长最快的领域 手术
最大的市场 北美洲

全球髓样甲状腺癌市场正在稳步增长，主要受发病率上升、诊断技术进步、治疗方式不断发展以及认识不断提高等因素推动。虽然它只占整个癌症市场的一小部分，但其独特的特性和对有效治疗的迫切需求使其成为一个活跃的研究和开发领域。

关键市场驱动因素

甲状腺癌发生率上升

主要市场挑战

治疗费用高昂

主要市场趋势

精准医疗的进展

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：甲状腺髓样癌市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗方法（手术、放射线治疗、化学疗法）
    • 按最终使用者（医院、放射治疗中心、癌症研究机构）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美髓样甲状腺癌市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第七章：欧洲髓样甲状腺癌市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区髓样甲状腺癌市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美洲髓样甲状腺癌市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲髓样甲状腺癌市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章：全球髓样甲状腺癌市场：SWOT 分析

第 14 章：竞争格局

  • AstraZeneca PLC
  • Sanofi AG
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co., Inc
  • Bayer AG
  • HUTCHMED Ltd.
  • Bristol-Myers Squibb Co.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 17529

Global Medullary Thyroid Cancer Market was valued at USD 1.45 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.45% through 2030. Medullary Thyroid Cancer (MTC) is a rare but clinically significant form of thyroid cancer that arises from the parafollicular cells (C cells) of the thyroid gland. It accounts for approximately 1-2% of all thyroid cancers. The Global Medullary Thyroid Cancer Market encompasses the various products, services, and treatments associated with the diagnosis, management, and research of this complex and challenging disease.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.45 Billion
Market Size 2030USD 2.36 Billion
CAGR 2025-20308.45%
Fastest Growing SegmentSurgery
Largest MarketNorth America

The Global Medullary Thyroid Cancer Market is witnessing steady growth, primarily driven by factors such as rising incidence rates, advancements in diagnostic technologies, evolving treatment modalities, and increasing awareness. While it represents a small segment of the overall cancer market, its unique characteristics and the pressing need for effective treatments make it an area of active research and development.

Key Market Drivers

Rising Prevalence of Thyroid Cancer

The rising prevalence of thyroid cancer is a significant driver of growth in the Global Medullary Thyroid Cancer (MTC) Market. In 2020, approximately 586,000 cases of thyroid cancer were recorded globally, positioning it as the 10th most prevalent cancer worldwide. The disease exhibited a significant gender disparity, with an estimated 449,000 cases in females compared to 137,000 cases in males, highlighting that thyroid cancer occurs at three times the rate in women relative to men. As more cases of thyroid cancer, including MTC, are diagnosed worldwide, the demand for diagnostic solutions, advanced treatments, and targeted therapies continues to rise. This increasing prevalence influences multiple market factors, from pharmaceutical innovation to healthcare infrastructure development, ultimately fueling market expansion. The growing incidence of thyroid cancer directly contributes to the demand for effective therapies, especially for rare subtypes like MTC. Medullary thyroid cancer (MTC) is a rare neuroendocrine malignancy, representing 1% to 5% of all diagnosed thyroid cancer cases, its unique clinical characteristics and aggressive nature necessitate specialized treatment approaches. Global thyroid cancer incidence has been steadily rising over the past two decades, partly due to improved screening programs. Studies show a higher detection rate of MTC cases, particularly in high-income countries with advanced healthcare infrastructure. As more patients are diagnosed with MTC, the market size for MTC-specific treatments expands. This encourages pharmaceutical companies to invest in drug development and clinical trials to meet the growing demand.

Key Market Challenges

High Treatment Costs

The cost of treating medullary thyroid cancer, particularly with advanced therapies and targeted medications, can be exorbitant. These high treatment costs pose a substantial challenge for patients, healthcare systems, and insurers. Patients may face financial strain, while healthcare providers may struggle to offer the latest treatments due to budget constraints. Additionally, insurers may impose restrictions on coverage for certain treatments.

Limited access to cutting-edge therapies for patients without adequate insurance coverage. Healthcare providers may need to make difficult decisions regarding resource allocation. Financial burden on patients may lead to treatment non-compliance and adverse outcomes.

Key Market Trends

Advancements in Precision Medicine

Precision medicine is revolutionizing the approach to treating medullary thyroid cancer. This trend involves tailoring treatments to individual patients based on their specific genetic mutations and disease characteristics. As our understanding of the genetic underpinnings of medullary thyroid cancer deepens, more targeted therapies are being developed. These therapies aim to inhibit the specific molecular pathways driving cancer growth, resulting in more effective and less toxic treatments.

Key Market Players

  • AstraZeneca PLC
  • Sanofi AG
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co., Inc
  • Bayer AG
  • HUTCHMED Ltd.
  • Bristol-Myers Squibb Co.

Report Scope:

In this report, the Global Medullary Thyroid Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Medullary Thyroid Cancer Market, By Treatment:

  • Surgery
  • Radiation Therapy
  • Chemotherapy

Medullary Thyroid Cancer Market, By End-User:

  • Hospitals
  • Radiation Therapy Center
  • Cancer Research Institutes

Medullary Thyroid Cancer Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Medullary Thyroid Cancer Market.

Available Customizations:

Global Medullary Thyroid Cancer market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Medullary Thyroid Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Surgery, Radiation Therapy, Chemotherapy)
    • 5.2.2. By End-User (Hospitals, Radiation Therapy Center, Cancer Research Institutes)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Medullary Thyroid Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Medullary Thyroid Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Medullary Thyroid Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Medullary Thyroid Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End User

7. Europe Medullary Thyroid Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Medullary Thyroid Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Medullary Thyroid Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Medullary Thyroid Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End User
    • 7.3.4. France Medullary Thyroid Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Medullary Thyroid Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End User

8. Asia-Pacific Medullary Thyroid Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Medullary Thyroid Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End User
    • 8.3.2. India Medullary Thyroid Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Medullary Thyroid Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Medullary Thyroid Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Medullary Thyroid Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End User

9. South America Medullary Thyroid Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Medullary Thyroid Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Medullary Thyroid Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Medullary Thyroid Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End User

10. Middle East and Africa Medullary Thyroid Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Medullary Thyroid Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Medullary Thyroid Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Medullary Thyroid Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Medullary Thyroid Cancer Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. AstraZeneca PLC
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Sanofi AG
  • 14.3. Eli Lilly and Company
  • 14.4. Exelixis, Inc.
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. Novartis AG
  • 14.7. Merck & Co., Inc
  • 14.8. Bayer AG
  • 14.9. HUTCHMED Ltd.
  • 14.10.Bristol-Myers Squibb Co.

15. Strategic Recommendations

16. About Us & Disclaimer